(Q36240739)

13 August 2017

1 reference

title

Clinical pharmacokinetics of imatinib (English)

1 reference

13 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Bin Peng

1

1 reference

13 August 2017

Peter Lloyd

series ordinal

2

1 reference

13 August 2017

Horst Schran

series ordinal

3

1 reference

13 August 2017

publication date

1 January 2005

1 reference

Clinical Pharmacokinetics

13 August 2017

published in

1 reference

13 August 2017

volume

44

1 reference

13 August 2017

issue

9

1 reference

13 August 2017

page(s)

879-894

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200544090-00001

13 August 2017

exact match

0 references

cites work

Practical management of patients with chronic myeloid leukemia receiving imatinib

1 reference

12 December 2020

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

1 reference

12 December 2020

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

1 reference

12 December 2020

Low concentrations of STI571 in the cerebrospinal fluid: a case report

1 reference

12 December 2020

Specific targeted therapy of chronic myelogenous leukemia with imatinib

1 reference

12 December 2020

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

1 reference

12 December 2020

Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.

1 reference

12 December 2020

Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone?

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

1 reference

12 December 2020

Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

1 reference

12 December 2020

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

12 December 2020

Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract

1 reference

12 December 2020

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients

1 reference

12 December 2020

Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants.

1 reference

12 December 2020

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

1 reference

12 December 2020

Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

1 reference

12 December 2020

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

1 reference

12 December 2020

High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry

1 reference

12 December 2020

Imatinib mesylate--a new oral targeted therapy

1 reference

12 December 2020

Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor

1 reference

12 December 2020

Effect of St John's wort on imatinib mesylate pharmacokinetics

1 reference

12 December 2020

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

12 December 2020

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry

1 reference

12 December 2020

1 reference

12 December 2020

Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

1 reference

12 December 2020

W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity

1 reference

12 December 2020

Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion

1 reference

12 December 2020

Multifaceted approach to the treatment of bcr-abl-positive leukemias.

1 reference

12 December 2020

Tyrphostins--potential antiproliferative agents and novel molecular tools

1 reference

12 December 2020

Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.

1 reference

12 December 2020

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia

1 reference

12 December 2020

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

1 reference

12 December 2020

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

12 December 2020

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

1 reference

12 December 2020

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

12 December 2020

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

12 December 2020

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

1 reference

12 December 2020

Imatinib mesylate, the first molecularly targeted gene suppressor

1 reference

12 December 2020

Chronic myelogenous leukemia

1 reference

12 December 2020

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

1 reference

12 December 2020

Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules

1 reference

12 December 2020

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

12 December 2020

Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.

1 reference

12 December 2020

The protein tyrosine kinase family of the human genome

1 reference

12 December 2020

Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance

1 reference

12 December 2020

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

1 reference

12 December 2020

1 reference

12 December 2020

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

12 December 2020

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

1 reference

12 December 2020

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

10.2165/00003088-200544090-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1018019066

0 references

1 reference